Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2020

01-12-2020 | Folic Acid | Study protocol

Is natural (6S)-5-methyltetrahydrofolic acid as effective as synthetic folic acid in increasing serum and red blood cell folate concentrations during pregnancy? A proof-of-concept pilot study

Authors: Kelsey M. Cochrane, Chantal Mayer, Angela M. Devlin, Rajavel Elango, Jennifer A. Hutcheon, Crystal D. Karakochuk

Published in: Trials | Issue 1/2020

Login to get access

Abstract

Background

North American health authorities recommend 0.4 mg/day folic acid before conception and throughout pregnancy to reduce the risk of neural tube defects. Folic acid is a synthetic form of folate that must be reduced by dihydrofolate reductase and then further metabolized. Recent evidence suggests that the maximal capacity for this process is limited and unmetabolized folic acid has been detected in the circulation. The biological effects of unmetabolized folic acid are unknown. A natural form of folate, (6S)-5-methyltetrahydrofolic acid (Metafolin®), may be a superior alternative because it does not need to be reduced in the small intestine. Metafolin® is currently used in some prenatal multivitamins; however, it has yet to be evaluated during pregnancy.

Methods/design

This double-blind, randomized trial will recruit 60 pregnant women aged 19–42 years. The women will receive either 0.6 mg/day folic acid or an equimolar dose (0.625 mg/day) of (6S)-5-methyltetrahydrofolic acid for 16 weeks. The trial will be initiated at 8–21 weeks’ gestation (after neural tube closure) to reduce the risk of harm should (6S)-5-methyltetrahydrofolic acid prove less effective. All women will also receive a prenatal multivitamin (not containing folate) to ensure adequacy of other nutrients. Baseline and endline blood samples will be collected to assess primary outcome measures, including serum folate, red blood cell folate and unmetabolized folic acid. The extent to which the change in primary outcomes from baseline to endline differs between treatment groups, controlling for baseline level, will be estimated using linear regression. Participants will have the option to continue supplementing until 1 week postpartum to provide a breastmilk and blood sample. Exploratory analyses will be completed to evaluate breastmilk and postpartum blood folate concentrations.

Discussion

This proof-of-concept trial is needed to obtain estimates of the effect of (6S)-5-methyltetrahydrofolic acid compared to folic acid on circulating biomarkers of folate status during pregnancy. These estimates will inform the design of a definitive trial which will be powered to assess whether (6S)-5-methyltetrahydrofolic acid is as effective as folic acid in raising blood folate concentrations during pregnancy. Ultimately, these findings will inform folate supplementation policies for pregnant women.

Trial registration

ClinicalTrials.gov, ID: NCT04022135. Registered on 14 July 2019.
Appendix
Available only for authorised users
Literature
1.
Shane B. Folate and vitamin B12, metabolism: Overview and interaction with riboflavin, vitamin B6, and polymorphisms. Food Nutr Bull. 2008;29(2 Suppl):S5–16; discussion S17–9.
2.
Pietrzik K, Bailey L, Shane B. Folic acid and l-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2010;49(8):535–48.PubMedCrossRef
3.
Blom HJ. Folic acid, methylation and neural tube closure in humans. Birth Defects Res A Clin Mol Teratol. 2009;85:295–302.PubMedCrossRef
4.
Food and Nutrition Board, Institute of Medicine. Folate. In: Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin and choline. Washington, DC: National Academy Press; 1998. p. 208–11.
5.
Health Canada. Multi-vitamin/mineral supplements monograph. 2018.
6.
Beaudin A, Stover P. Insights into metabolic mechanisms underlying folate-responsive neural tube defects: a minireview. Birth Defects Res A Clin Mol Teratol. 2009;85(4):274–84.PubMedPubMedCentralCrossRef
7.
Douglas Wilson R, Audibert F, Brock JA, Carroll J, Cartier L, Gagnon A, et al. Pre-conception folic acid and multivitamin supplementation for the primary and secondary prevention of neural tube defects and other folic acid-sensitive congenital anomalies. J Obstet Gynaecol Canada. 2015;37(6):534–49.CrossRef
8.
Daly LE, Kirke P, Molloy A, Weir D, Scott J. Folate levels and neural tube defects. JAMA. 1995;274(21):1698–702.PubMedCrossRef
9.
Group MVSR. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338(8760):131–7.CrossRef
10.
Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992;327(26):1832–5.PubMedCrossRef
11.
Ami N, Bernstein M, Boucher F, Rieder M, Parker L. Folate and neural tube defects: the role of supplements and food fortification. Paediatr Child Health. 2016;21(3):145–9.PubMedPubMedCentralCrossRef
12.
De Wals P, Tairou F, Van Allen M, Uh S, Lowry B, Sibbald B, et al. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med. 2007;357:135–42.PubMedCrossRef
13.
Boulet SL, Yang Q, Mai C, Kirby RS, Collins JS, Robbins JM, et al. Trends in the postfortification prevalence of spina bifida and anencephaly in the United States. Birth Defects Res Part A Clin Mol Teratol. 2008;82:527–32.PubMedCrossRef
14.
15.
Dubois L, Diasparra M, Bedard B, Colapinto C, Fontaine-Bisson B, Morisset A, et al. Adequacy of nutritional intake from food and supplements in a cohort of pregnant women in Québec, Canada: The 3D Cohort Study (Design, Develop, Discover). Am J Clin Nutr. 2017;106(2):541–8.PubMedCrossRef
16.
Pfeiffer CM, Johnson CL, Jain RB, Yetley EA, Picciano MF, Rader JI, et al. Trends in blood folate and vitamin B12 concentrations in the United States, 1988-2004. Am J Clin Nutr. 2007;86:718–27.PubMedCrossRef
17.
Macfarlane AJ, Greene-finestone LS, Shi Y. Vitamin B12 and homocysteine status in a folate-replete population: results from the Canadian Health Measures Survey 1. Am J Clin Nutr. 2011;94:1079–87.PubMedCrossRef
18.
Houghton LA, Sherwood KL, Pawlosky R, Ito S, Connor DLO. [6S]-5-methyltetrahydrofolate is at least as effective as folic acid in preventing a decline in blood folate concentrations during lactation. Am J Clin Nutr. 2006;83:842–50.PubMedCrossRef
19.
Plumptre L, Masih SP, Ly A, Aufreiter S, Sohn K-J, Croxford R, et al. High concentrations of folate and unmetabolized folic acid in a cohort of pregnant Canadian women and umbilical cord blood. Am J Clin Nutr. 2015;102(4):848–57.PubMedCrossRef
20.
Colapinto CK, Connor DLO, Tremblay MS. Folate status of the population in the Canadian Health Measures Survey. CMJA. 2011;183(2):E100–6.
21.
Bailey SW, Ayling JE. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. Proc Natl Acad Sci U S A. 2009;106(36):15424–9.PubMedPubMedCentralCrossRef
22.
Palchetti CZ, Paniz C, de Carli E, Marchioni DM, Colli C, Steluti J, et al. Association between serum unmetabolized folic acid concentrations and folic acid from fortified foods. J Am Coll Nutr. 2017;36(7):572–8.PubMedPubMedCentralCrossRef
23.
Patanwala I, King MJ, Barrett DA, Rose J, Jackson R, Hudson M, et al. Folic acid handling by the human gut: implications for food fortification and supplementation. Am J Clin Nutr. 2014;100:593–9.PubMedPubMedCentralCrossRef
24.
Kelly P, McPartlin J, Goggins M, Weir DGW, Scott JM. Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am Soc Clin Nutr. 1997;65:1790–5.CrossRef
25.
Sweeney MR, McPartlin J, Weir DG, Scott JM. Measurements of sub-nanomolar concentrations of unmetabolised folic acid in serum. J Chromatogr B Anal Technol Biomed Life Sci. 2003;788(1):187–91.CrossRef
26.
Sweeney MR, McPartlin J, Weir DG, Daly L, Scott JM. Postprandial serum folic acid response to multiple doses of folic acid in fortified bread. Br J Nutr. 2006;95(1):145–51.PubMedCrossRef
27.
Sweeney MR, Mcpartlin J, Scott J. Folic acid fortification and public health: report on threshold doses above which unmetabolised folic acid appear in serum. BMC Public Health. 2007;7(41):1–7.
28.
Tam C, O’Connor D, Koren G. Circulating unmetabolized folic acid: relationship to folate status and effect of supplementation. Obstet Gynecol Int. 2012;2012:1–17.CrossRef
29.
Kelly P, McPartlin J, Scott J. A combined high-performance liquid chromatographic-microbiological assay for serum folic acid. Anal Biochem. 1996;238(2):179–83.PubMedCrossRef
30.
Fohr IP, Prinz-Langenohl R, Brönstrup A, Bohlmann AM, Nau H, Berthold HK, et al. 5,10-methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women. Am J Clin Nutr. 2002;75(2):275–82.PubMedCrossRef
31.
Kalmbach RD, Choumenkovitch SF, Troen AM, D’Agostino R, Jacques PF, Selhub J. Circulating folic acid in plasma: relation to folic acid fortification. Am J Clin Nutr. 2008;88(3):763–8.PubMedPubMedCentralCrossRef
32.
Lamers Y, Macfarlane AJ, Connor DLO, Fontaine-bisson B. Periconceptional intake of folic acid among low-risk women in Canada: summary of a workshop aiming to align prenatal folic acid supplement composition with current expert guidelines. Am J Clin Nutr. 2018;108:1357–68.PubMedPubMedCentralCrossRef
33.
Page R, Robichaud A, Arbuckle TE, Fraser WD, MacFarlane AJ. Total folate and unmetabolized folic acid in the breast milk of a cross-section of Canadian women. Am J Clin Nutr. 2017;105(5):1101–9.PubMedCrossRef
34.
Houghton LA, Yang J, O’Connor DL. Unmetabolized folic acid and total folate concentrations in breast milk are unaffected by low-dose folate supplements. Am J Clin Nutr. 2009;89(1):216–20.PubMedCrossRef
35.
Verwei M, Arkbåge K, Mocking H, Havenaar R, Groten J. The binding of folic acid and 5-methyltetrahydrofolate to folate-binding proteins during gastric passage differs in a dynamic in vitro gastrointestinal model. J Nutr. 2004;134(1):31–7.PubMedCrossRef
36.
Nygren-Babol L, Jägerstad M. Folate-binding protein in milk: a review of biochemistry, physiology, and analytical methods. Crit Rev Food Sci Nutr. 2012;52(5):410–25.PubMedCrossRef
37.
38.
Henderson AM, Aleliunas RE, Loh SP, Khor GL, Harvey-Leeson S, Glier MB, et al. L-5-methyltetrahydrofolate supplementation increases blood folate concentrations to a greater extent than folic acid supplementation in Malaysian women. J Nutr. 2018;148:855–90.CrossRef
39.
Lamers Y, Prinz-langenohl R, Bramswig S, Pietrzik K. Red blood cell folate concentrations increase more after supplementation with [6S]-5-methyltetrahydrofolate than with folic acid in women of childbearing age. Am J Clin Nutr. 2006;84:156–61.PubMedCrossRef
40.
Venn BJ, Green T, Moser R, Mann JI. Comparison of low-dose supplementation with L-5-methylterahydrofolate or folic acid on plasma homocysteine: a randomized placebo controlled study. Am J Clin Nutr. 2003;77:658–62.PubMedCrossRef
41.
Lamers Y, Prinz-Langenohl R, Moser R, Pietrzik K. Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in healthy women. Am J Clin Nutr. 2004;79:473–8.PubMedCrossRef
42.
Pietrzik K, Lamers Y, Brämswig S, Prinz-Langenohl R. Calculation of red blood cell folate steady state conditions and elimination kinetics after daily supplementation with various folate forms and doses in women of childbearing age. Am J Clin Nutr. 2007;86:1414–9.PubMedCrossRef
43.
Chan A, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.PubMedPubMedCentralCrossRef
44.
45.
Clifford AJ, Noceti EM, Block-Joy A, Block T, Block G. Erythrocyte folate and its response to folic acid supplementation is assay dependent in women. J Nutr. 2005;135(1):137–43.PubMedCrossRef
46.
Campbell K, Rowe H, Azzam H, Lane CA. The management of nausea and vomiting of pregnancy. J Obstet Gynaecol Canada. 2016;38(12):1127–37.CrossRef
47.
Sutton EF, Cain LE, Vallo PM, Redman LM. Strategies for successful recruitment of pregnant patients into clinical trials. Obstet Gynecol. 2017;129(3):554–9.PubMedPubMedCentralCrossRef
48.
PHAC. What Mothers Say: The Canadian Maternity Experiences Survey. What Mothers Say: The Canadian Maternity Experiences Survey. 2009.
49.
Udipi S, Kirksey A, Roepke J. Diurnal variations in folacin levels of human milk: use of a single sample to represent folacin concentration in milk during a 24-h period. Am J Clin Nutr. 1987;45:770–9.PubMedCrossRef
50.
Molloy AM, Scott JM. Microbiological assay for serum, plasma, and red cell folate using cryopreserved, microtiter plate method. Methods Enzymol. 1997;281:43–53.PubMedCrossRef
51.
Pirkle J. CDC Laboratory Procedure Manual; total folate, serum/whole blood microbiological assay; 2012.
52.
Pfeiffer CM, Fazili Z, McCoy L, Zhang M, Gunter EW. Determination of folate vitamers in human serum by stable-isotope-dilution tandem mass spectrometry and comparison with radioassay and microbiologic assay. Clin Chem. 2004;50(2):423–32.PubMedCrossRef
53.
Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr. 1998;157(S2):252–62.CrossRef
54.
Arning E, Bottiglieri T. Quantitation of S-adenosylmethionine and S-adenosylhomocysteine in plasma using liquid chromatography-electrospray tandem mass spectrometry. In: Methods in molecular biology; 2016. p. 255–62.
55.
Ubbink JB, Serfontein WJ, De Villiers LS. Stability of pyridoxal-5-phosphate semicarbazone: applications in plasma vitamin B6 analysis and population surveys of vitamin B6 nutritional status. J Chromatogr B Biomed Sci Appl. 1985;342(C):277–84.CrossRef
56.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–3.PubMedCrossRef
57.
Selhub J, Arnold R, Smith AM, Picciano MF. Milk folate binding protein (FBP): a secretory protein for folate? Nutr Res. 1984;4(2):181–7.CrossRef
58.
Little RJ, Agostino RD, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355–60.PubMedPubMedCentralCrossRef
Metadata
Title
Is natural (6S)-5-methyltetrahydrofolic acid as effective as synthetic folic acid in increasing serum and red blood cell folate concentrations during pregnancy? A proof-of-concept pilot study
Authors
Kelsey M. Cochrane
Chantal Mayer
Angela M. Devlin
Rajavel Elango
Jennifer A. Hutcheon
Crystal D. Karakochuk
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Trials / Issue 1/2020
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-020-04320-3

Other articles of this Issue 1/2020

Trials 1/2020 Go to the issue

Correction

Correction to: Cluster identification, selection, and description in Cluster randomized crossover trials: the PREP-IT trials

Study protocol

Individualized treatment for acute Achilles tendon rupture based on the Copenhagen Achilles Rupture Treatment Algorithm (CARTA): a study protocol for a multicenter randomized controlled trial

Letter

ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial

Study protocol

Death Cafés for prevention of burnout in intensive care unit employees: study protocol for a randomized controlled trial (STOPTHEBURN)

Study protocol

Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial)

Study protocol

An automated structured education intervention based on a smartphone app in Chinese patients with type 1 diabetes: a protocol for a single-blinded randomized controlled trial